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Abstract: Cyclo-oxygenase (COX)-2 selective and nonselective nonsteroidal anti-inflamma-
tory drugs (NSAIDs) are important in managing acute and chronic pain secondary to inflamma-
tion. As a greater understanding of the risks of gastrointestinal (GI), cardiovascular (CV) and
renal events with NSAIDs use has emerged, guidelines have evolved to reflect differences in
risks among NSAIDs. Updated guidelines have yet to reflect new evidence from recent trials
which showed similar CVevent rates with celecoxib compared to naproxen and ibuprofen, and
significantly better GI tolerability for celecoxib. This practice advisory paper aims to present
consensus statements and associated guidance regarding appropriate NSAID use based on a
review of current evidence by a multidisciplinary group of expert clinicians. This paper is
especially intended to guide primary care practitioners within Asia in the appropriate use of
NSAIDs in primary care. Following a literature review, group members used a modified Delphi
consensus process to determine agreement with selected recommendations. Agreement with a
statement by 75% of total voting members was defined a priori as consensus. For low GI risk
patients, any nonselective NSAID plus proton pump inhibitor (PPI) or celecoxib alone is
acceptable treatment when CV risk is low; for high CV risk patients, low-dose celecoxib or
naproxen plus PPI is appropriate. For high GI risk patients, celecoxib plus PPI is acceptable for
low CV risk patients; low-dose celecoxib plus PPI is appropriate for high CV risk patients, with
the alternative to avoid NSAIDs and consider opioids instead. Appropriate NSAID prescription
assumes that the patient has normal renal function at commencement, with ongoing monitoring
recommended. In conclusion, appropriate NSAID use requires consideration of all risks.
Keywords: cardiovascular risk, COX-2 selective inhibitors, gastrointestinal risk,
nonsteroidal anti-inflammatory drugs, osteoarthritis, inflammation
Introduction
Chronic pain is one of the most common causes of disability worldwide and is
routinely observed in the primary care setting.1 The presence of inflammation is a
key underlying mechanism of chronic pain and is a key contributor to the patho-
physiology of rheumatic conditions, including rheumatoid arthritis, spondyloarthro-
pathies and osteoarthritis (OA).2,3 These conditions have a major impact in terms of
health burden and adverse effects on quality of life in affected people throughout
the world, and especially in developing countries including those in Asia.4
Moreover, with an aging population, the prevalence of chronic pain will continue
to rise and the role of the primary care practitioner (PCP) as care providers and
prescribers of analgesic medications will become more important.
Consistent with an inflammatory mechanism, common analgesics used in the
management of chronic pain include paracetamol and nonsteroidal anti-inflammatory
Correspondence: Kok Yuen Ho
The Pain Clinic, Mt Alvernia Hospital, 820
Thomson Road, #07-59 Mt Alvernia
Medical Centre D, 574623, Singapore,
Tel/Fax +65 6254 5447
Email drho@thepainclinic.com.sg
Journal of Pain Research Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Journal of Pain Research 2020:13 1925–1939 1925
http://doi.org/10.2147/JPR.S247781
DovePress © 2020 Ho et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
 
Jo
ur
na
l o
f P
ain
 R
es
ea
rc
h 
do
wn
loa
de
d 
fro
m
 h
ttp
s:/
/w
ww
.d
ov
ep
re
ss
.co
m
/ b
y 8
6.
5.
89
.1
78
 o
n 
17
-S
ep
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nly
.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
drugs (NSAIDs). Although considered a first-line analgesic,
paracetamol provides limited short-term clinical benefit and
is associated with side effects of hepatotoxicity and
hypertension.5–8 Opioids are also prescribed in cases requir-
ing step-up pain relief and when pain is thought to have a
non-inflammatory etiology. In addition to side effects of
nausea, vomiting and constipation, the over-prescription of
opioids has led to a sharp increase in the prevalence of opioid
addiction and epidemic levels of associated morbidity and
mortality.9 NSAIDs, which in terms of prescribing patterns
are often the bridge between paracetamol and opioids, are
commonly used to treat inflammation through their actions
on the cyclo-oxygenase (COX) enzyme, which is found in
two distinct isoforms, COX-1 and COX-2.10,11 Whereas
inhibition of COX-2 confers relief from inflammation and
pain, COX-1 inhibition commonly leads to gastrointestinal
(GI) and renal side effects.12,13
NSAIDs may be either nonselective in that they inhibit
both COX-1 and COX-2, or selective in that they only
inhibit COX-2 (coxibs).13 The COX-2 selective NSAIDs,
celecoxib and rofecoxib, were the first members of the
new class to be introduced in the 1990s in an attempt to
reduce GI side effects associated with NSAID use.
However, rofecoxib was withdrawn from the market in
2004 due to its association with an increased incidence
of cardiovascular (CV) adverse events.14,15 Research pub-
lished in the decade after rofecoxib’s market withdrawal
attempted to further elucidate the safety of NSAIDs, with
an emphasis on determining whether the CV concerns
associated with rofecoxib use were a class effect of coxibs.
CV risk not only varied among different COX-2 selective
NSAIDs (the CV risk was higher for rofecoxib than cel-
ecoxib), but when considered overall, serious CV events
for nonselective NSAIDs compared with COX-2 selective
NSAIDs occurred at approximately equal rates.16 In some
studies, elevated risk was associated with certain nonse-
lective NSAIDs, such as out-of-hospital cardiac arrest and
major adverse cardiac events (MACE) in the case of
diclofenac.17,18 Thus, COX-selectivity is not binary, with
the COX-2 isoform alone not defining the CV risk of an
NSAID.19 Moreover, NSAIDs have been shown to have
differential effects on blood pressure (BP), with rofecoxib,
etoricoxib and the nonselective NSAID ibuprofen demon-
strating greater increases in systolic BP than celecoxib.20–
22 This has obvious implications because hypertension is a
known risk factor for CV adverse events. Finally, recent
data from the PRECISION trial have shown the noninfer-
iority of celecoxib when compared to ibuprofen and
naproxen with regard to CV safety.23 Ibuprofen and
naproxen, in contrast, had greater GI and renal toxicity.
Among PCPs, there is often a lack of awareness of the
CV, GI and renal risks associated with the use of
NSAIDs.24 As a result, PCPs may not routinely identify
patient risk factors before prescribing NSAIDs.
Conversely, there may be an overestimation of NSAID-
associated risk, leading to prescription of suboptimal doses
for pain relief. In addition, patients are largely unaware of
the potential harms associated with nonselective NSAID
use when taking over-the-counter products.25 Moreover,
updated practice recommendations are needed to reflect
data from recent trials. At present, the only available
COX-2 selective inhibitors are celecoxib, etoricoxib and
parecoxib. Celecoxib and etoricoxib are available as oral
preparations, whereas parecoxib is the injectable prodrug
of valdecoxib. Rofecoxib and valdecoxib have been with-
drawn from market due to concerns over CV safety and
serious dermatological reactions, respectively; lumiracoxib
has been withdrawn because of risk of liver toxicity.26,27
The aim of this practice advisory is to summarize the
current evidence regarding NSAID use and provide
updated guidance to PCPs on prescription of oral
NSAIDs, with an emphasis on CV, GI and renal safety.
Materials and Methods
In November 2018, an expert meeting was convened in
Kuala Lumpur, Malaysia involving a multidisciplinary
group of clinicians to discuss the appropriate use of
NSAIDs. The objectives of the meeting were to review
current clinical data for NSAIDs including data for
PRECISION and other international studies on NSAIDs,
and identify knowledge gaps regarding NSAID use in
Asia. Members of the group included specialists in pain
management, orthopaedic surgery, neurology, cardiology,
gastroenterology, nephrology and rheumatology from
Indonesia (Rizaldy Pinzon, Sumariyono Sarmidi), Japan
(Ken Nakata, Shuichi Tsuruoka), Korea (Ji Hyeon Ju),
Malaysia (Mary Cardosa, Ozlan Kamil, Sabarul
Mokhtar), Philippines (Sandra Navarra), Singapore (Kok
Yuen Ho, Heng Boon Yim), Thailand (Sumapa
Chaiamnuay), Vietnam (Ho Huynh Quang Tri, Nguyen
Van Hung), and the United Kingdom (Ernest Choy).
At the meeting, the group agreed to develop a practice
advisory document to guide Asian PCPs in the appropriate
use of NSAIDs in the primary care setting. The group
selected pertinent topics to include in two succeeding
online meetings. Members of the group were assigned to
Ho et al Dovepress
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individual topics, with group representatives conducting a
MEDLINE search for relevant articles dated from January
1, 2000, and limited to English language articles. Relevant
articles were selected and reviewed, and assigned mem-
bers subsequently developed proposals for ten clinically
relevant consensus statements relating to NSAID use to
represent the group’s clinical practice recommendations
for Asian PCPs. The consensus process was a modification
of the Delphi method, with members of the voting group
asked to rate their agreement with each recommendation
on a 5-point Likert scale (ie, 5, strongly agree; 4, agree; 3,
neither agree nor disagree; 2, disagree; 1, strongly dis-
agree). Agreement by 75% of total voting members
based on the proportion of members who either strongly
agreed or agreed with a statement was defined a priori as
consensus achieved for a statement. Consensus was
achieved for all statements in the first voting round.
Consequently, members of the group were not required
to reconvene as originally planned to discuss modifications
of the consensus statements based on feedback from the
first voting round.
Current Evidence
Beyond COX selectivity, there are marked differences in
the molecular and chemical properties of individual drugs
even when comparing within the respective subclasses
(Table 1).28–31 For example, ibuprofen and naproxen are
both derivatives of propionic acid, whereas diclofenac is a
benzeneacetic derivative; celecoxib and valdecoxib both
have a sulfonamide group, whereas etoricoxib and rofe-
coxib have a sulfonyl group.32 Although all NSAIDs are
acidic compounds, the acid dissociation constant (pKa)
varies from 9.7 for celecoxib to 4.0 for diclofenac.31
Compared with COX-2 selective NSAIDs, the nonselec-
tive NSAIDs are weak acids. Among the COX-2 selective
NSAIDs, selectivity for the COX-2 enzyme varies consid-
erably, with greater selectivity for the discontinued drugs
lumiracoxib, rofecoxib and valdecoxib, as well as etori-
coxib, and lower selectivity for celecoxib.19
These differences in molecular structure and chemistry
naturally confer different pharmacologic properties on the
individual drugs. The weak acidity of nonselective
NSAIDs confers detergent properties on account of their
lipophilicity. This allows interactions with phospholipids
of the brush border, increasing cell permeability, and pro-
moting damage to the epithelial lining of the gut.31,33
Weaker acidity may also be associated with the loss of
cellular integrity due to pH-dependent effects that involve
NSAID-mediated uncoupling of oxidative phosphorylation
and reduced intracellular ATP production.31 The sulfonyl
group associated with rofecoxib, but not the sulfonamide
group of celecoxib or the chemical structures of other
nonselective NSAIDs, has been shown to increase the
susceptibility of low-density lipoprotein (LDL)-cholesterol
and related lipids to oxidative modification independent of
COX-2 inhibition.34 This nonenzymatic oxidation of LDL-
cholesterol contributes to atherogenesis and CV disease.
Gastrointestinal Risks
Endoscopic evidence of mucosal injury in the upper GI
tract is common with chronic use of NSAIDs, affecting as
many as 70% of chronic users compared with 10% of
people not taking NSAIDs.35 In one meta-analysis, all
NSAID regimens including nonselective and COX-2
selective agents were shown to increase the risk of upper
GI complications.36 Although ulceration and related bleed-
ing are much less common events, the mechanism of
NSAID-mediated GI injury is the same. Previously, this
was explained in terms of COX-1-dependent depletion of
prostaglandins and the subsequent impairment of the pro-
tective role of prostaglandins in stimulating the synthesis
and secretion of mucus and bicarbonate, as well as pro-
moting epithelial proliferation.37 However, it is now appar-
ent that inhibition of both COX-1 and COX-2 must occur
to spur gastric ulceration, with the reduced impact of
COX-2 selective NSAIDs on GI toxicity thus explained
by the absence of dual COX inhibition rather than any
COX-1 sparing effects.14,37-39
Factors that increase the risk of GI toxicity with NSAID
use include older age, history of peptic ulcer disease/compli-
cations, Helicobacter pylori infection, high-dose NSAID
use, and concomitant use of certain drugs, including corti-
costeroids, anticoagulants and antiplatelet agents. Age-
related risk reflects the tendency of chronic pain medication
use among an older age cohort (≥60 years) with an increased
likelihood of comorbidities and potential complications asso-
ciated with polypharmacy.30,31 A pooled analysis of 21 ran-
domized controlled trials (RCTs) showed that among elderly
arthritis patients, the use of celecoxib reduced the incidence
of GI adverse events including abdominal pain, constipation,
diarrhea, dyspepsia, flatulence and nausea compared with
naproxen, ibuprofen or diclofenac.40 In another meta-analy-
sis of more than 50,000 patients enrolled in 52 RCTs, when
compared with nonselective NSAIDs, celecoxib was asso-
ciated with a significantly lower risk of all clinically signifi-
cant GI events throughout the entire GI tract.41 In the
Dovepress Ho et al
Journal of Pain Research 2020:13 submit your manuscript | www.dovepress.com
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Table 1 Molecular and Chemical Properties of Cyclo-Oxygenase (COX)-2 Selective and Nonselective Nonsteroidal Anti-
Inflammatory Drugs
Compound Status Classification Chemical
Structure
Acidity (pK) COX-1/
COX-2 IC50
Ratio*
Clinical Implications
Celecoxib Licensed in all
markets
COX-2–selective,
sulfonamide
structure
9.7 (low) 30
(moderate)
Low intestinal permeability, no
effect on lipid-oxidation
susceptibility
Rofecoxib Withdrawn
from market
COX-2–selective,
methylsulfone
structure
8.6
(intermediate)
272 (high) Intermediate intestinal
permeability, increased lipid-
oxidation susceptibility
Etoricoxib Not FDA
approved,
licensed in EU
COX-2–selective,
methylsulfone
structure
4.5
(moderate)
344 (very
high)
Moderate intestinal
permeability, heightened lipid-
oxidation susceptibility
Parecoxib FDA
withdrawn,
licensed in EU
COX-2–selective,
sulfonamide
structure
6.7
(moderate)
60
(intermediate)
increased lipid-oxidation
susceptibility
Valdecoxib Withdrawn
from market
COX-2–selective,
sulfonamide
structure
9.8 (low) 60
(intermediate)
Low intestinal permeability,
increased lipid-oxidation
susceptibility
Lumiracoxib Withdrawn
from market
COX-2–selective,
arylalkanoic acid
structure
4.7
(moderate)
400 (highest) Moderate intestinal
permeability, heightened lipid-
oxidation susceptibility
Diclofenac Licensed in all
markets
Acetic acid
derivative
4.0
(moderate)
12 (low) Moderate intestinal
permeability, no effect on lipid-
oxidation susceptibility
Ibuprofen Licensed in all
markets
Propionic acid
derivative
5.2
(moderate)
≤1 (very low) Moderate intestinal
permeability, no effect on lipid-
oxidation susceptibility
(Continued)
Ho et al Dovepress
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MEDAL program, which evaluated the gastrointestinal
safety of etoricoxib compared with diclofenac in almost
35,000 patients with OA and rheumatoid arthritis (RA),
etoricoxib was associated with significantly fewer upper GI
events than diclofenac.42 However, the difference between
etoricoxib and diclofenac was explained by a reduction in
uncomplicated events in the etoricoxib arm, but not in the
more serious complicated events.
In the context of all NSAID therapy, H. pylori infection
increases the risk of ulceration and bleeding, and its era-
dication prior to commencing long-term antiplatelet ther-
apy is recommended to reduce GI risk.31 The risk of GI
toxicity increases at high NSAID doses,36 but even at
standard doses the risks are not negligible: the CLASS
study showed that the risk of upper GI ulceration was
higher for standard doses of ibuprofen or diclofenac com-
pared with celecoxib administered at doses greater than
those indicated clinically.38 In addition to antiplatelet ther-
apy, GI risk is increased with concomitant use of corticos-
teroids and selective serotonin reuptake inhibitors
(SSRIs).37,43
Appropriate assessment of patient GI risk includes age,
prior GI ulceration or bleeding, use of gastroprotective
agents, and use of corticosteroids and other medications.44,45
In addition to assessment, the risk of GI toxicity with NSAID
use can be mitigated through regular monitoring to facilitate
the early detection of injury and appropriate treatment.
Hemoglobin levels can be used as an indicator of GI injury,
with low hemoglobin and hematocrit attributable to blood
loss in the absence of other potential causes.30 A drop in
hemoglobin of ≥2 g/dL is a well-recognized surrogate end-
point for investigating NSAID-associated GI toxicity in clin-
ical trials.
One strategy used to minimize the risk of GI complica-
tions involves the coadministration of NSAIDs with a
proton pump inhibitor (PPI).46 Such coadministration is
generally regarded as safe and is recommended in guide-
lines. However, recent evidence challenging this view
suggests that in addition to the adverse effects of PPIs,
their coadministration with NSAIDs may potentiate the GI
risks of the latter.30 In particular, PPIs have been shown to
alter gut microbiome composition leading to the risk of
bacterial overgrowth and contributing to a low-grade,
chronic inflammation that can exacerbate NSAID-induced
mucosal injury of the small bowel.30 In some patients at
least, the use of PPIs may increase the risk of bone
fractures, Clostridium difficile and other enteric infections,
and gastric cancer.47,48 Extrapolation of results of the
CONDOR trial and related studies also suggest that PPI
prophylaxis may be unnecessary in some long-term
NSAID users.39,49,50 The CONDOR trial evaluated cele-
coxib compared with diclofenac plus omeprazole in
patients with OA and RA. The findings showed that the
risk of a clinically significant upper or lower GI event was
lower in patients treated with a COX-2 selective NSAID
compared with a nonselective NSAID plus PPI.50 In
patients at high risk of GI bleeding, concomitant PPI use
remains an appropriate strategy for managing GI risk,
particularly when prescribed in accordance with any risk
factors.37 In the MEDAL program, the reduction in
uncomplicated GI events with etoricoxib compared with
diclofenac was maintained in patients treated with PPIs.42
Preventative strategies for GI toxicity may be used
both for primary and secondary prevention, and include
the eradication of H. pylori and use of PPIs as already
discussed, together with the use of enteric-coated NSAIDs
and high-dose H2 receptor antagonists (H2RAs).
37,51
Evidence suggests that enteric-coating of NSAIDs does
not reduce the incidence of upper GI complications com-
pared with other formulations, but may shift the site of
Table 1 (Continued).
Compound Status Classification Chemical
Structure
Acidity (pK) COX-1/
COX-2 IC50
Ratio*
Clinical Implications
Naproxen Licensed in all
markets
Propionic acid
derivative
4.2
(moderate)
≤1 (very low) Moderate intestinal
permeability, no effect on lipid-
oxidation susceptibility
Notes: Table derived from information presented in references.28–31 *COX-2 selectivity based on the IC80 (80% inhibitory concentration) of COX-2 relative to COX-1 in
human whole blood assays.
Abbreviations: COX-1, cyclo-oxygenase-1; COX-2, cyclo-oxygenase-2; EU, European Union; FDA, US Food and Drug Administration.
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injury to more distal regions of the gut.30 The use of PPI
prophylaxis is likely to be more effective than the use of
H2RAs, with the latter protective at high doses, but inef-
fective at reducing the risk of gastric ulcers at lower
doses.52 Although the use of PPI prophylaxis can improve
GI tolerability during chronic NSAID administration and
may also prevent upper GI complications, video endo-
scopy has shown that the risk of small bowel lesions
remains even in healthy subjects.39 Furthermore, the ben-
eficial effects of PPIs on upper GI complications do not
extend to the lower GI tract, with PPI use unable to
prevent NSAID or aspirin-associated lower GI bleeding.53
Another gastroprotective strategy involves the use of mis-
oprostol, which is effective at preventing upper GI bleed-
ing in high-risk patients and may be appropriate in case of
intolerance to PPIs.54 There is also support for H. pylori
eradication particularly in Asia where the prevalence is
high,55–57 but available data suggest that H. pylori eradica-
tion in infected patients is at best equivalent to PPIs in
preventing GI complications and may even be inferior.30
Cardiovascular Risks
As the previous experience with rofecoxib demonstrates,
there is also the potential for adverse CV events with
NSAIDs. Already discussed, the proatherogenic potential
of rofecoxib which was shown in the VIGOR trial to
manifest as an increased risk of CV events compared
with placebo14,15,58,59 may arise as a consequence of none-
nzymatic oxidation.34 However, experimental evidence
that COX-2 inhibition may contribute to a prothrombotic
state has placed suspicion on COX-2 selective inhibitors in
general.60 In particular, by suppressing vasodilation and
the anti-aggregation effects associated with prostacyclin
production, and leaving COX-1-dependent platelet throm-
boxane (TX) A2 synthesis unopposed, COX-2 selective
inhibitors may increase platelet aggregation via prostacy-
clin blockade and thus promote thrombosis.58,61 COX-
dependent inhibition of prostaglandin synthesis may also
contribute to sodium and water retention, worsening heart
failure, hypertension, and effects on the renal system.21,62
At a mechanistic level, there are differences among
NSAIDs. For example, celecoxib but not rofecoxib
reduces endothelial tissue-factor expression, a key initiator
of the coagulation cascade, and may thus have a lower
prothrombotic potential.61,63
Considering CV safety, there is considerable evidence
that different COX-2 selective inhibitors and non-selective
NSAIDs have different CV safety profiles.18,23,64 For
example, the nonselective NSAID diclofenac presents sig-
nificantly greater CV risk compared with ibuprofen,
naproxen, paracetamol, and non-analgesic use.18 In the
MEDAL study, the COX-2 selective NSAID etoricoxib
was associated with a similar risk of thrombotic events
to diclofenac,65 while at moderate doses, celecoxib
afforded similar CV safety to ibuprofen and naproxen.23
Naproxen use compared with other NSAIDs has pre-
viously been associated with a protective effect against
acute myocardial infarction (MI).66 However, in meta-
analyses, all NSAIDs including naproxen were associated
with an increased risk of acute MI,67 and most increased
the risk of heart failure.36 Real-world data also suggest a
heightened CV risk with NSAID use.64 Among the dis-
continued COX-2 selective inhibitors, the TARGET RCT
showed in more than 18,000 patients with OA that lumi-
racoxib had similar CV safety to ibuprofen and naproxen,
irrespective of aspirin use.68 However, findings of a post
hoc analysis of TARGET subsequently suggested that ibu-
profen may confer an increased risk of both thrombotic
events and congestive heart failure events compared with
lumiracoxib among aspirin users at high CV risk.69 In a
subsequent meta-analysis of six trials, there were no sig-
nificant differences in CV outcomes between lumiracoxib
and placebo or other NSAIDs in patients with OA.70 The
APPROVe study compared rofecoxib with placebo in
patients with a history of colorectal adenomas and showed
an increase in the composite endpoint of nonfatal MI,
nonfatal stroke and death from CV, hemorrhagic and
unknown causes for patients receiving rofecoxib.71
The SCOT and PRECISION studies are useful in fram-
ing the evidence related to the CV safety of NSAIDs.
SCOT enrolled patients aged 60 years and older with OA
or RA and without established CV disease who were
taking prescribed chronic nonselective NSAIDs.72
Switching to celecoxib resulted in a similar rate of CV
events as continuing on prescribed nonselective NSAIDs;
GI safety was improved with celecoxib, though more
patients assigned to nonselective NSAIDs remained on
treatment. PRECISION assessed the noninferiority of cel-
ecoxib compared with ibuprofen and naproxen with
respect to the primary composite outcome of CV death,
nonfatal MI or nonfatal stroke, also in patients with OA
and RA.23 At approved dosages (mean daily dose 209 mg),
celecoxib was associated with a significantly lower risk of
GI events whereas overall CV safety was similar for the
three drugs. However, allocation to ibuprofen compared
with celecoxib was associated with a significant increase
Ho et al Dovepress
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in systolic BP and a higher rate of new onset
hypertension.21 Among patients with symptomatic arthritis
who had at least a moderate CV risk, patients using
naproxen or ibuprofen had a significantly higher risk of a
major toxicity, including time to first occurrence of
MACE, important GI events, renal events, and all-cause
mortality.73 Among non-selective NSAIDs, naproxen may
be preferred over ibuprofen. In one study, ibuprofen and
diclofenac were associated with an increased early risk of
out-of-hospital cardiac arrest.17 Further, the use of ibupro-
fen in patients receiving aspirin as secondary prevention of
MI may abrogate the benefits of aspirin.74
The MEDAL program similarly showed differences
between a nonselective and a COX-2 selective NSAID in
terms of BP effects. However, unlike PRECISION whose
findings favored celecoxib compared with ibuprofen, the
use of etoricoxib in MEDAL was associated with signifi-
cantly increased systolic BP compared with diclofenac.75
A subsequent study concluded that baseline BP rather than
the BP-elevating effects of etoricoxib explained the risk of
thrombotic events.76
Celecoxib may thus be associated with increased CV
risk, but only at dosages that are substantially higher than
recommended.77 Indeed, greater risk of MI and MACE
have been documented for higher doses of NSAIDs, with
risk in the case of MI also greatest during the first month
of use.64,67 Greater CV risk may also be associated with
older age, and related concerns regarding comorbidities
and polypharmacy.
Renal Risks
In addition to the GI and CV effects of NSAIDs, epide-
miological and pathologic data also associate NSAID use
with the potential for both acute and chronic kidney dis-
ease (CKD).78–84 Renal side effects which include sodium
and water retention with edema, hyponatremia, hyperkale-
mia, and acute kidney injury may precipitate renal failure
resulting in acute dialysis.62,85 Risk factors include older
age, renal impairment, heart failure, liver disease, diabetes
mellitus (DM), and concurrent prescription with antihyper-
tensive drugs (eg, diuretics, renin-angiotensin system
inhibitors).62,86,87 Again, mechanisms of NSAID-induced
kidney damage relate to inhibition of prostaglandin synth-
esis and are dose- and duration-dependent.80,81 Low levels
of COX-2 are constitutively expressed in the macula
densa, with COX-2 inhibition leading to a reduction in
renal blood flow and resulting functional impairment.
NSAIDs may also accumulate in renal tubular cells during
secretion. While NSAID-induced sodium retention is
COX-2-mediated, NSAID-induced reductions in glomeru-
lar filtration rate are mediated via COX-1.13
Consistent with the dual COX-1/COX-2-dependent
mechanisms, which predict the possibility of differences
in renal toxicity for different NSAIDs, there are limited
data to suggest clinically relevant differences.84,88 In the
MEDAL program, etoricoxib had a greater risk of reno-
vascular adverse events than diclofenac.65 In PRECISION,
the risk of renal events was significantly lower with cel-
ecoxib compared with ibuprofen, and was similar for
celecoxib compared with naproxen.23 In a meta-analysis,
NSAIDs with high COX-2 selectivity had a lower associa-
tion with acute kidney injury (AKI) compared to NSAIDs
with low COX-2 selectivity.83 Overall, NSAIDs have a
low but tangible risk in causing AKI, electrolyte imbal-
ances and increased BP, but their role in progressive kid-
ney disease is associated only with long-term use in high
cumulative doses.78 In patients with CKD, withdrawal of
NSAID use is recommended by nephrology consensus
groups, but initiation of alternatives such as opioids con-
veys different and no less important drug-related
concerns.89,90 In a study conducted in China that included
age- and sex-matched controls of NSAID users, long-term
(≥48 months) use of NSAIDs was independently asso-
ciated with reduced renal function.91 It is recommended
that patients with risk factors for renal impairment have
preventative strategies in place that include using the low-
est effective NSAID dose for the shortest possible time, as
well as monitoring renal function, fluid retention and elec-
trolyte abnormalities.62,92 The concomitant use of NSAIDs
and angiotensin converting enzyme (ACE) inhibitors
should be avoided.
Practice Advisory Statement
Screening for CV, GI and Renal Risk
Factors Prior to Initiating NSAID Therapy
Statement 1: Prior to initiating NSAID therapy for a
patient, the following factors must be taken into con-
sideration. (Level of agreement: strongly agree, 86%;
agree, 14%; consensus, 100%).
Age, associated medical comorbidities, previous medical or
surgical history, concomitant use of medications (particularly
antiplatelet medications, anticoagulants, corticosteroids,
ACE inhibitors and SSRIs), H. pylori infection, and BP
monitoring should be taken into consideration before
Dovepress Ho et al
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initiating NSAID therapy. The use of aspirin increases bleed-
ing risk even at low cardioprotective doses, with bleeding
risk also increased when non-aspirin NSAIDs are combined
with aspirin.93 Furthermore, coadministration of aspirin and
most other NSAIDs can lead to drug–drug interactions,
which is based on competition for access to the acetylation
site of platelet-expressed COX-1. Non-aspirin NSAIDs drive
the reversible, transient inhibition of platelet aggregation,
thus blocking aspirin’s irreversible inhibition and potentially
allowing clot formation. Although aspirin maintains its car-
dioprotective benefits in the presence of non-aspirin
NSAIDs,94 the combination of aspirin and ibuprofen has
been shown to increase the risk of a CVevent.95,96
Several meta-analyses have reviewed the potential for
SSRIs to cause upper GI bleeding. All have reported an
increased risk of such bleeding when SSRIs are used alone
and especially in combination with NSAIDs.97–100 Caution
is advised when there is a need to administer both medica-
tion classes in combination.
As discussed, H. pylori infection has a high prevalence
in Asian patients, which has important implications for
potential GI risk. NSAID use and H. pylori infection are
independent risk factors for GI complications,101,102 with
synergism for the development of peptic ulcer and bleed-
ing found when NSAIDs are used in patients with H.
pylori infection. Conversely, peptic ulcer disease is rare
in people who are negative for H. pylori infection.101 This
provides a rationale for eradicating H. pylori in patients
requiring chronic NSAID use. Moreover, eradication of H.
pylori prior to the start of long-term NSAID use is asso-
ciated with a reduced risk of ulcers and appears to be
especially effective in NSAID drug-naïve patients.103−105
Patients requiring long-term treatment with NSAIDs and
with epigastric pain or dyspepsia, or otherwise assessed as
high GI risk, should be referred to a gastroenterologist for
a detailed evaluation, including H. pylori testing and pos-
sible gastroscopy; those testing positive for H. pylori may
be offered eradication therapy.
Statement 2: Consider taking a baseline complete
blood count and renal function test (if not previously
available) in the following patients. (Level of agree-
ment: strongly agree, 64%; agree, 36%; consensus,
100%).
In patients with a history of renal impairment, conges-
tive heart failure, elevated BP and/or type 2 diabetes
mellitus, or the presence of unexplained anemia, consider
a complete blood count and assessment of renal function
prior to initiating an NSAID.
Statement 3: Use NSAIDs with caution in the following
high-risk patients. (Level of agreement: strongly agree,
79%; agree, 21%; consensus, 100%).
Patients at high risk of NSAID-associated adverse events
may be stratified according to GI, CVand renal risk. Patients
considered to be at high GI risk are those with age greater
than 65 years, use of high-dose NSAIDs, history of peptic
ulcer and related complications, and concurrent use of
aspirin, anti-platelet therapy or anti-coagulant therapy (and
especially patients receiving double anti-platelet therapy).
Patients at high CV risk are those with a history of acute
coronary syndrome or percutaneous/surgical coronary revas-
cularization, stable angina and angiographic evidence of sig-
nificant coronary artery stenosis, a history of stroke/transient
ischemic attack, documented significant carotid artery steno-
sis, or congestive heart failure. Patients at high renal risk are
those with age greater than 75 years, impaired renal function
based on estimated glomerular filtration rate less than 60mL/
min, and concomitant administration of an antihypertensive
from any of the diuretic, angiotensin converting enzyme
(ACE) inhibitor, or angiotensin receptor blocker (ARB)
classes. Analgesics such as paracetamol, tramadol or codeine
may be used in place of NSAIDs if the risks of NSAID
treatment outweigh the potential benefits. However, the effi-
cacy, availability and potential adverse effects of these alter-
natives also need to be considered in any decision-making
regarding appropriate analgesia.
Choice of NSAIDs
All oral nonselective NSAIDs and COX-2 selective inhi-
bitors have analgesic effects of a similar magnitude, but
differences may exist among individual drugs in terms of
potential GI, CV, renal or liver toxicities.106
Statement 4: The choice of NSAID should depend on
patient risk profile, pathophysiology of the pain condi-
tion, duration of therapy, and efficacy/side effects of the
drug. Level of agreement: strongly agree, 93%; agree,
7%; consensus, 100%).
Statement 5: The lowest effective dose and for the
shortest duration, consistent with treatment goals,
Ho et al Dovepress
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remains the guiding principle. (Level of agreement:
strongly agree, 100%; consensus, 100%).
Statement 6: Current GI protective therapies are gen-
erally adequate for protection of the upper GI tract of
NSAID users. (Level of agreement: strongly agree,
21%; agree, 57%; consensus, 78%).
This statement was a point of contention among the group
and represents a compromise from the original statement,
which was formulated as: GI protective therapies are generally
inadequate or inappropriate in NSAID users. Consensus was
not formed for this statement, necessitating rephrasing of the
statement to the above wording (Level of agreement: strongly
agree, 21%; agree, 43%; consensus, 64% [not reached]). In
line with the revision, the group agreed that GI protective
therapies (eg, PPIs) benefit patients who require an NSAID
and who have a moderate to high risk for upper GI
complications.37,46,51,54 There is little or no evidence to sup-
port any protection against lower GI side effects.
Statement 7: COX-2 selective NSAIDs are superior to
nonselective NSAIDs for preventing both upper and
lower GI tract adverse events. (Level of agreement:
strongly agree, 43%; agree, 57%; consensus, 100%).
CONDOR, a large RCT that compared upper and lower GI
safety of celecoxib with that of diclofenac plus omeprazole in
patientswithOAandRA,was thefirst trial to show thatGI risk
throughout the GI tract was significantly reduced in patients
treated with a COX-2 selective inhibitor compared with a
nonselective NSAID.41,50 Along with the SUCCESS trial and
the MEDAL program, which also showed superior upper GI
safety for celecoxib and etoricoxib, respectively, compared
with nonselective NSAIDs, these data support the statement
that COX-2 selective NSAIDs are superior to nonselective
NSAIDs in the prevention of GI adverse events.
Statement 8: Both nonselective NSAIDs and COX-2
selective NSAIDs may increase renal adverse effects.
(Level of agreement: strongly agree, 36%; agree, 64%;
consensus, 100%).
The findings of ameta-analysis showing that NSAIDswith
high COX-2 selectivity (≥5-fold) had a lower association with
AKI than NSAIDs with lower (<5-fold) COX-2 selectivity
together with findings from PRECISION showing a lower
risk of renal events with celecoxib compared with ibuprofen
provide some evidence of differences in renal risk based on
individual NSAID selection.23,83
Statement 9: The treatment algorithm should consider
the renal function, GI risk and CV risk profile of the
patient. (Level of agreement: strongly agree, 79%;
agree, 21%; consensus, 100%).
All NSAIDs have features that are useful to highlight from
a safety perspective. Among the nonselective NSAIDs,
although diclofenac has the least risk of GI side effects, it
also has the highest risk of CV events while also associated
with increased risk of hepatic impairment. Based on data from
PRECISION, ibuprofen not only has a higher risk than cele-
coxib ofGI side effects, but is also associatedwith a higher risk
of new-onset hypertension.21,23,73 In addition, ibuprofen and
diclofenac use carries a higher risk of cardiac arrest compared
with celecoxib.17 Based on findings of the MEDAL study,
etoricoxib has a comparable risk to diclofenac of thrombotic
CV events but a higher risk of renovascular events.65
Etoricoxib use is also associated with dose-related increases
in risk of hypertension, edema and congestive heart failure.65
In patients taking aspirin for secondary stroke or cor-
onary thrombosis prevention, COX-2 selective NSAIDs
are the drugs of choice due to the potential for COX-1-
associated drug–drug interactions and, in particular, the
known risks of combining aspirin with ibuprofen.93
While previous guidelines have recommended that
naproxen plus PPI or celecoxib plus PPI can be given in
patients with high GI and high CV risk, for patients taking
low-dose aspirin the use of celecoxib plus PPI is the better
choice. As shown in PRECISION, celecoxib has better
overall GI safety than ibuprofen or naproxen despite treat-
ment with low-dose aspirin or corticosteroids.107
Based on data from PRECISION, a toxicity risk score that
predicts the one-year risk of major toxicity has been validated
among NSAID users.108 Major toxicity included MACE, AKI,
significant GI events and mortality. In the derivation cohort
from PRECISION, significant variables that predicted
increased risk of a major toxicity were age, male sex, history
of CV disease, hypertension, DM, tobacco use, statin use,
elevated serum creatinine, hematocrit level, and type of arthritis.
Based on an individual patient’s calculated risk score, the
patient can be classified into one of three categories, including
low risk (<1%), moderate risk (1–4%) and high risk (≥4%).
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An updated treatment algorithm is provided, which
supports recommended NSAID prescribing practices
based on GI, CV and renal risk factors (Figure 1).
Statement 10: Regularly monitor for drug adverse
events, including high blood pressure and signs of GI
bleeding. (Level of agreement: strongly agree, 79%;
agree, 21%; consensus, 100%).
BP should be measured at each visit, and laboratory
tests should be conducted at least once yearly to determine
blood counts and renal function.
Conclusion
Inflammation is common in many chronic pain conditions
where the burden of disease is high. NSAIDs are an effective
therapy for such conditions, but appropriate risk evaluation is
important when selecting an NSAID in order to balance
efficacy and risk. This practice advisory serves to update
previously published guidelines, and in particular offers
PCPs a simplified approach to choosing an appropriate
NSAID for pain management based on recent evidence and
according to the risk profile of individual patients. In this
regard, all NSAIDs have a safety profile that requires con-
sideration of GI, CVand renal risk. Whereas GI and CV risk
were previously acknowledged according to COX-1 and
COX-2 selectivity, respectively, it is apparent that this is too
simplistic and appropriate risk management requires consid-
eration of the individual (ie, non-class) effects of each
NSAID. Having chosen an appropriate NSAID, there is an
ongoing need for patient monitoring and risk assessment.
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